Mutual Fund Series Trust > Mutual Fund Series Trust
Eventide Healthcare & Life Sciences Fund
$1.59B
Avg Monthly Net Assets
$1.45B
Total Assets
$12.70M
Total Liabilities
$1.44B
Net Assets
Eventide Healthcare & Life Sciences Fund is a Mutual Fund in Mutual Fund Series Trust
from Mutual Fund Series Trust,
based in Nebraska,
United States of America.
The fund has four share classes
and monthly net assets of $1.59B.
On August 29th, 2024 it reported 95 holdings, the largest
being Celldex Therapeutics Inc. (4.0%), Mirum Pharmaceuticals Inc. (4.0%) and Vaxcyte Inc (3.9%).
Data provided by Fincoded.
Share Classes
| Name | Class/Contract ID | Ticker | Monthly Returns (2 years) |
|---|---|---|---|
| Eventide Healthcare & Life Sciences Fund Class A | C000121707 | ETAHX | |
| Eventide Healthcare & Life Sciences Fund Class C | C000121708 | ETCHX | |
| Eventide Healthcare & Life Sciences Fund Class I | C000121710 | ETIHX | |
| Eventide Healthcare & Life Sciences Fund Class N | C000121709 | ETNHX |
Holdings
From latest NPORT-P, filed August 29th, 2024 for period ending June 30th, 2024.
Historic holdings data available from Fincoded.
| Name | Profile | Category | Country | Value $USD | # Shares | % of Fund |
|---|---|---|---|---|---|---|
| 4D MOLECULAR THE (4D Molecular Therapeutics Inc) | Long | Equity-common | US | $18M | 881K | 1.28 |
| ALNYLAM PHARMACE (Alnylam Pharmaceuticals Inc.) | Long | Equity-common | US | $21M | 87K | 1.47 |
| ANAPTYSBIO INC (AnaptysBio Inc.) | Long | Equity-common | US | $14M | 568K | 0.99 |
| APELLIS PHARMACE (Apellis Pharmaceuticals Inc) | Long | Equity-common | US | $8M | 210K | 0.56 |
| ARCH ONCOLOGY IN (ARCH ONCOLOGY INC) | Long | Equity-preferred | US | $129K | 5M | 0.01 |
| ARDELYX INC | Long | Equity-common | US | $30M | 4M | 2.10 |
| ARGENX SE - ADR | Long | Equity-common | NL | $27M | 63K | 1.88 |
| ARROWHEAD PHARMA (Arrowhead Pharmaceuticals Inc) | Long | Equity-common | US | $12M | 464K | 0.84 |
| AURA BIOSCIENCES (Aura Biosciences Inc.) | Long | Equity-common | US | $44M | 6M | 3.04 |
| Avalyn Pharma | Long | Equity-preferred | US | $15M | 20M | 1.04 |
| AVIDITY BIOSCIEN (Avidity Biosciences Inc.) | Long | Equity-common | US | $15M | 376K | 1.07 |
| AXSOME THERAPEUT (Axsome Therapeutics Inc.) | Long | Equity-common | US | $40M | 497K | 2.78 |
| BETA BIONIC SERIES B | Long | Equity-preferred | US | $7M | 941K | 0.49 |
| BETA BIONICS B2 | Long | Equity-preferred | US | $6M | 809K | 0.43 |
| BETA BIONICS CL D WARRANT (Beta Bionics Series D) | Long | Derivative-other | US | $2M | 333K | 0.15 |
| Beta Bionics Inc | Long | Equity-preferred | US | $4M | 482K | 0.25 |
| BETA BIONICS INC SERIES C | Long | Derivative-other | US | $892K | 121K | 0.06 |
| BETA BIONICS INC SERIES D (Beta Bionics Series D) | Long | Equity-common | US | $4M | 476K | 0.31 |
| BIOHAVEN LTD | Long | Equity-common | VG | $22M | 635K | 1.53 |
| Biosplice Therapeutics (BIOSPLICE THERAPEUTICS INC.) | Long | Derivative-other | US | $0 | 103K | – |
| BioSplice Therapeutics | Long | Equity-preferred | US | $0 | 295K | – |
| BISPL F 03/12/2025 (BIOSPLICE THERAPEUTICS INC. SERIES C) | Long | Debt | US | $395K | – | 0.03 |
| BLUEPRINT MEDICI (Blueprint Medicines Corporation) | Long | Equity-common | US | $25M | 232K | 1.73 |
| BRIDGEBIO PHARMA (Bridgebio Pharma Inc) | Long | Equity-common | US | $15M | 579K | 1.02 |
| BRIDGEBIO PHARMA | Long | Equity-common | US | $3M | 138K | 0.24 |
| CASMA SER B2 (CASMA THERAPEUTICS) | Long | Equity-preferred | US | $1M | 5M | 0.07 |
| CASMA THERAPEUTI (CASMA THERAPEUTICS) | Long | Equity-preferred | US | $1M | 5M | 0.07 |
| CASMA THERAPEUTICS (CASMA THERAPEUTICS, INC.) | Long | Equity-preferred | US | $381K | 2M | 0.03 |
| CASMA THERAPEUTICS II | Long | Equity-preferred | US | $414K | 2M | 0.03 |
| CELCUITY INC (Celcuity Inc.) | Long | Equity-common | US | $25M | 2M | 1.74 |
| CELLDEX THERAPEU (Celldex Therapeutics Inc.) | Long | Equity-common | US | $58M | 2M | 4.01 |
| CEREVEL THERAPEU (Cerevel Therapeutics Holdings Inc) | Long | Equity-common | US | $20M | 490K | 1.39 |
| COGENT BIOSCIENC (Cogent Biosciences Inc.) | Long | Equity-common | US | $12M | 1M | 0.82 |
| COLLEGIUM PHARMA (Collegium Pharmaceutical Inc.) | Long | Equity-common | US | $41M | 1M | 2.87 |
| CRINETICS PHARMA (Crinetics Pharmaceuticals Inc.) | Long | Equity-common | US | $33M | 735K | 2.28 |
| CYTOKINETICS INC | Long | Equity-common | US | $14M | 254K | 0.96 |
| DYNAVAX TECHNOLO (Dynavax Technologies Corp.) | Long | Equity-common | US | $18M | 2M | 1.24 |
| DYNE THERAPEUTIC (Dyne Therapeutics Inc.) | Long | Equity-common | US | $17M | 485K | 1.19 |
| EVOLENT HEALTH-A (Evolent Health, Inc.) | Long | Equity-common | US | $28M | 1M | 1.92 |
| EXACT SCIENCES (Exact Sciences Corporation) | Long | Equity-common | US | $24M | 566K | 1.66 |
| FID-MM GOVT-I (Fidelity Institutional Cash Portfolios) | Long | Short-term investment vehicle | US | $3M | – | 0.24 |
| Flare Series A Tranche 2 (FLARE THERAPEUTICS INCORPORATED) | Long | Equity-preferred | US | $1M | 902K | 0.08 |
| FLARE THERAPEUTI (FLARE THERAPEUTICS INC) | Long | Equity-preferred | US | $1M | 1M | 0.09 |
| FLARE THERAPEUTICS (CASMA THERAPEUTICS II) | Long | Equity-preferred | US | $2M | 2M | 0.16 |
| Freenome | Long | Equity-preferred | US | $220K | 134K | 0.02 |
| Freenome Holdings (FREENOME HOLDINGS, INC.) | Long | Equity-preferred | US | $2M | 930K | 0.11 |
| FRST AM-GV OB-U (First American Funds Inc.) | Long | Short-term investment vehicle | US | $31M | – | 2.13 |
| GERON CORP (Geron Corp.) | Long | Equity-common | US | $27M | 6M | 1.87 |
| GLAUKOS CORP (Glaukos Corp.) | Long | Equity-common | US | $8M | 64K | 0.52 |
| GOLDFINCH BIO B2 | Long | Equity-preferred | US | $0 | 4M | – |
| GOLDFINCH BIOPHARMA INC | Long | Equity-preferred | US | $0 | 5M | – |
| GOLDFINCH BIOPHARMA INC B | Long | Equity-preferred | US | $0 | 8M | – |
| GUARDANT HEALTH (Guardant Health Inc) | Long | Equity-common | US | $42M | 1M | 2.91 |
| IDEAYA BIOSCIENC (IDEAYA Biosciences Inc.) | Long | Equity-common | US | $12M | 335K | 0.82 |
| INARI MEDICAL IN (Inari Medical Inc) | Long | Equity-common | US | $30M | 620K | 2.07 |
| INOZYME PHARMA I (Inozyme Pharma Inc) | Long | Equity-common | US | $18M | 4M | 1.22 |
| INSMED INC | Long | Equity-common | US | $45M | 675K | 3.14 |
| INSPIRE MEDICAL (Inspire Medical Systems Inc) | Long | Equity-common | US | $17M | 125K | 1.16 |
| IRHYTHM TECHNOLO (Irhythm Technologies Inc) | Long | Equity-common | US | $29M | 272K | 2.03 |
| KEROS THERAPEUTI (Keros Therapeutics Inc.) | Long | Equity-common | US | $23M | 499K | 1.58 |
| Kojin Therapeutics | Long | Equity-preferred | US | $467K | 763K | 0.03 |
| KOJIN THERAPEUTICS INC | Long | Equity-preferred | US | $467K | 763K | 0.03 |
| KORRO BIO INC | Long | Equity-common | US | $5M | 160K | 0.38 |
| KORRO BIO INC. | Long | Equity-common | US | $13M | 369K | 0.87 |
| KRYSTAL BIOTECH (Krystal Biotech Inc) | Long | Equity-common | US | $25M | 136K | 1.74 |
| KYMERA THERAPEUT (Kymera Therapeutics Inc) | Long | Equity-common | US | $14M | 462K | 0.96 |
| LEXEO THERAPEUTI (Lexeo Therapeutics Inc) | Long | Equity-common | US | $33M | 2M | 2.32 |
| LEXEO THERAPEUTICS (Lexeo Therapeutics Inc) | Long | Equity-common | US | $21M | 1M | 1.43 |
| METAGENOMI INC | Long | Equity-common | US | $544K | 133K | 0.04 |
| METAGENOMI-MGXR (Metagenomi Inc) | Long | Equity-common | US | $2M | 450K | 0.13 |
| MIRUM PHARMACEUT (Mirum Pharmaceuticals Inc.) | Long | Equity-common | US | $58M | 2M | 4.00 |
| MIRUM PHARMACEUTICALS (MIRUM PHARMACEUTICALS, INC.) | Long | Equity-common | US | $5M | 152K | 0.36 |
| NEKTAR THERAPEUT (Nektar Therapeutics) | Long | Equity-common | US | $9M | 8M | 0.65 |
| OCULAR THERAPEUTIX INC | Long | Equity-common | US | $16K | 2K | 0.00 |
| PELOTON THERAPEU (PELOTON THERAPEUTICS) | Long | Equity-preferred | US | $1M | 2M | 0.09 |
| PRIVIA HEALTH GR (Privia Health Group Inc.) | Long | Equity-common | US | $1M | 76K | 0.09 |
| PROMETHEUS LABORATORIES (PROMETHEUS BIOSCIENCES) | Long | Equity-preferred | US | $702K | 1M | 0.05 |
| R1 RCM INC (R1 RCM Inc.) | Long | Equity-common | US | $17M | 1M | 1.20 |
| RAPPORT THERAPEU (Rapport Therapeutics Inc) | Long | Equity-common | US | $1M | 50K | 0.08 |
| REPLIGEN CORP (Repligen Corporation) | Long | Equity-common | US | $15M | 119K | 1.04 |
| REVOLUTION MEDIC (Revolution Medicines Inc) | Long | Equity-common | US | $25M | 651K | 1.75 |
| ROCKET PHARMACEU (Rocket Pharmaceuticals Inc) | Long | Equity-common | US | $17M | 771K | 1.15 |
| SAREPTA THERAPEU (Sarepta Therapeutics Inc) | Long | Equity-common | US | $36M | 229K | 2.51 |
| SCHOLAR ROCK HOL (Scholar Rock Holding Corp.) | Long | Equity-common | US | $14M | 2M | 0.97 |
| SHORELINE BIOSCIENCES B | Long | Equity-preferred | US | $13M | 1M | 0.88 |
| TG THERAPEUTICS (TG Therapeutics Inc) | Long | Equity-common | US | $13M | 719K | 0.89 |
| TRANSMEDICS GROU (TransMedics Group Inc.) | Long | Equity-common | US | $32M | 214K | 2.24 |
| TURNSTONE BIOLOG (Turnstone Biologics Corp) | Long | Equity-common | US | $1M | 458K | 0.08 |
| UNITED THERAPEUT (United Therapeutics Corporation) | Long | Equity-common | US | $22M | 68K | 1.50 |
| US BANK MMDA - USBGFS 9 | Long | Short-term investment vehicle | US | $30M | – | 2.09 |
| VAXCYTE INC | Long | Equity-common | US | $56M | 739K | 3.87 |
| VERACYTE INC | Long | Equity-common | US | $12M | 564K | 0.85 |
| VERONA PHAR-ADR (Verona Pharma Plc) | Long | Equity-common | GB | $8M | 528K | 0.53 |
| VIKING THERAPEUT (Viking Therapeutics Inc.) | Long | Equity-common | US | $13M | 253K | 0.93 |
| ZENTALIS PHARMAC (Zentalis Pharmaceuticals Inc) | Long | Equity-common | US | $20M | 5M | 1.40 |
Address
Mutual Fund Series Trust
4221 North 203rd Street Suite 100
Elkhorn
Nebraska
68130
United States of America
Directors
Stephen P. Lachenauer
Jerry Szilagyi
Tobias Caldwell
Tiberiu Weisz
Transfer Agents
Ultimus Fund Solutions, LLC
Pricing Services
ICE Data Services
Custodians
US Bancorp
Shareholder Servicing Agents
Ultimus Fund Solutions, LLC
Admins
Ultimus Fund Solutions, LLC
Brokers
FCSTONE